The short version of Nicotinamide mononucleotide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-22. Anything still debated is marked as such rather than presented as settled.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide intermediate in NAD+ salvage pathway |
| Common abbreviation | NMN | Also written as β-NMN |
| Molecular formula | C11H15N2O8P | Uncharged parent form |
| Molar mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | For β-nicotinamide mononucleotide |
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
It was found intact in a nearby field. Despite early reports with lurid headlines asserting that the thieves were "likely doomed", the radiation sickness was mild enough that the suspects were quickly released to police custody, and no one is known to have died from the incident.
Iodine-131 (131I, I-131) is a radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production. It also plays a major role as a radioactive isotope present in nuclear fission products, and was a significant contributor to the health hazards from open-air atomic bomb testing in the 1950s, and from the Chernobyl disaster, as well as being a large fraction of the contamination hazard in the first weeks in the Fukushima nuclear crisis. This is because 131I is a major fission product of uranium and plutonium, comprising nearly 3% of the total products of fission (see fission product yield). Due to its beta decay, iodine-131 causes mutation and death in cells that it penetrates, and other cells up to several millimeters away. For this reason, high doses of the isotope are sometimes less dangerous than low doses, since they tend to kill thyroid tissues that would otherwise become cancerous as a result of the radiation. For example, children treated with moderate dose of 131I for thyroid adenomas had a detectable increase in thyroid cancer, but children treated with a much higher dose did not. Likewise, most studies of very-high-dose 131I for treatment of Graves' disease have failed to find any increase in thyroid cancer, even though there is linear increase in thyroid cancer risk with 131I absorption at moderate doses.
Starting in 2007, Jimmy John's began sponsoring NASCAR, first with Steven Wallace in 2007 and 2008. In 2009 and 2010, Jimmy John's sponsored Kevin Harvick in the NASCAR Nationwide Series. In 2011, Jimmy John's and Richard Childress Racing reached a multi-year agreement to sponsor Harvick for the Sprint Cup Series. The 2014 sponsorship continued with Harvick and the Stewart–Haas Racing team. On September 13, 2014, Jimmy John's became the title sponsor of the Jimmy John's Freaky Fast 300 at Chicagoland Speedway. Harvick won the 2014 NASCAR Sprint Cup Championship, giving Jimmy John's their first championship. From 2010 to 2019, Jimmy John's entered into an Ultimate Fighting Championship sponsorship with Brock Lesnar with logos appearing on his trunks. This sponsorship extended to WWE upon Lesnar's return to that company in 2012, making him the only WWE performer in history to be permitted such a deal. In 2015, Jimmy John's co-sponsored the RCH Factory Racing Supercross and Motocross team featuring Ken Roczen. The team contested both the Monster Energy AMA Supercross and the Lucas Oil Pro Motocross championships. In June, Jimmy John's sponsored former NASCAR champion Rusty Wallace for his Speed Energy Formula Off-Road debut at the 2015 X Games.
All lactic acid bacteria (LAB) involved in winemaking, whether as a positive contributor or as a source for potential faults, have the ability to produce lactic acid through the metabolism of a sugar source, as well as the metabolism of L-malic acid. Species differ in how they metabolise the available sugars in wine (both glucose and fructose, as well as the unfermentable pentoses that wine yeasts do not consume). Some bacteria species use the sugars through a homofermentative pathway, meaning only one main end product (usually lactate) is produced, while others use heterofermentative pathways that can create multiple end products such as carbon dioxide, ethanol, and acetate. While only the L-isomer of lactate is produced by LAB in the conversion of malic acid, both hetero- and homofermenters can produce D-, L- and DL-isomers of lactic from glucose which may contribute to slightly different sensory properties in the wine. While O. oeni is often the LAB most desired by winemakers to complete malolactic fermentation, the process is most often carried out by a variety of LAB species that dominate the must at different points during fermentations. Several factors influence which species will be dominant, including fermentation temperature, nutritional resources, the presence of sulfur dioxide, interaction with yeast and other bacteria, pH, and alcohol levels (Lactobacillus species, for example, tend to prefer higher pH and can tolerate higher alcohol levels than O. oeni), as well as initial inoculation (such as "wild" ferments versus an inoculation of cultured O. oeni).
Further development of IWP derivatives resulted in improved IWP-based ATP-competitive inhibitors of CK1δ. In summary, it can be concluded that the cellular effects mediated by IWPs are not only due to the inhibition of Porcn, but also to inhibition of CK1δ dependent signaling pathways. These data clearly show a high potential of CK1δ specific inhibitors for personalized therapy concepts for the treatment of various tumor entities (e.g. breast cancer, colorectal cancer, and glioblastoma), leukemia, neurodegenerative disease like AD, PD, and ALs, and sleeping disorders. Furthermore, CK1δ specific inhibitors seem to exhibit high relevance for prognostic applications. In this context [11C] labeled highly potent difluoro-dioxolo-benzoimidazol-benzamides can be used as PET radiotracers and for imaging of AD. Since small molecule inhibitors often have various disadvantages, including low bioavailability, off-target effects as well as severe side effects, the interest in the development and validation of new biological tools like identification of biological active peptides either able to inhibit CK1δ activity or the interaction of CK1δ with cellular proteins is more and more growing. The use of peptide libraries resulted in the identification of peptides able to specifically block the interaction of CK1δ with tubulin, the RNA helicase DDX3X and Axin. Binding of peptide δ-361 to α-tubulin not only lead to blocking of the interaction of CK1δ with α-tubulin, it also selectively inhibited phosphorylation of GST-α-tubulin by CK1δ.
Sources: en.wikipedia.org
== Selected publications == Eaton, D. L., & Groopman, J. D. (Eds.). (1994). The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance. Academic Press. ISBN 978-0122282553. Ramsdell, H. S., & Eaton, D. L. (1990). Species differences in aflatoxin B1 metabolism in hepatic microsomes and hepatocytes from monkey, rat, mouse, and chicken. Toxicol. Appl. Pharmacol., 105(2), 216–225. Gallagher, E. P., Wienkers, L. C., Stapleton, P. L., Kunze, K. L., & Eaton, D. L. (1994). Role of human microsomal cytochrome P4503A4 and 1A2 in the bioactivation of aflatoxin B1. Cancer Research, 54(1), 101–108. Eaton, D. L., & Bammler, T. K. (1999). Concise review of the glutathione S-transferases and their significance in toxicology. Toxicological Sciences, 49(2), 156–164. National Academies of Sciences, Engineering, and Medicine; Eaton, D. L. et al. (Eds.). (2018). Public Health Consequences of E-Cigarettes. The National Academies Press. ISBN 978-0309468336. Chang, S.-Y., Weber, E. J., Sidorenko, V. S., Chapron, A., Yeung, C. K., Gao, C., Mao, Q., Shen, D., Wang, J., Rosenquist, T. A., Dickman, K. G., Grollman, A. P., *Kelly, E. J., Himmelfarb, J., & Eaton, D. L. (2017). Human liver-kidney microphysiological system for quantum dot toxicity testing and aristolochic acid nephrotoxicity modeling. JCI Insight, 2(6), e91320 Omenn GS & Eaton DL. (2022). The Risk Assessment-Risk Management Paradigm. IN: M. Robson and WA Toscano, Ed. Risk Assessment for Environmental Health, 2nd Edition, Chapter 2, John Wiley & Sons, New York.
== Physiological relevance == Phosphatases act in opposition to kinases/phosphorylases, which add phosphate groups to proteins. The addition of a phosphate group may activate or de-activate an enzyme (e.g., kinase signalling pathways) or enable a protein-protein interaction to occur (e.g., SH2 domains ); therefore phosphatases are integral to many signal transduction pathways. Phosphate addition and removal do not necessarily correspond to enzyme activation or inhibition, and that several enzymes have separate phosphorylation sites for activating or inhibiting functional regulation. CDK, for example, can be either activated or deactivated depending on the specific amino acid residue being phosphorylated. Phosphates are important in signal transduction because they regulate the proteins to which they are attached. To reverse the regulatory effect, the phosphate is removed. This occurs on its own by hydrolysis, or is mediated by protein phosphatases. Protein phosphorylation plays a crucial role in biological functions and controls nearly every cellular process, including metabolism, gene transcription and translation, cell-cycle progression, cytoskeletal rearrangement, protein-protein interactions, protein stability, cell movement, and apoptosis. These processes depend on the highly regulated and opposing actions of PKs and PPs, through changes in the phosphorylation of key proteins. Histone phosphorylation, along with methylation, ubiquitination, sumoylation and acetylation, also regulates access to DNA through chromatin reorganisation.
== See also == Ministry of Inter Provincial Coordination Eighteenth Amendment to the Constitution of Pakistan Federalism in Pakistan Constitution of Pakistan Inter-State Commission Inter-State Council
=== Interviews and promotional press === Vulture published an interview with Clipse in which an album was explicitly confirmed, on June 19, 2024—one day after "The Birds Don't Sing" was previewed at the Louis Vuitton's Men's Spring–Summer Show 2025. Interviewed by Craig Jenkins, the duo reflected on the passing of their parents and how that experience, along with Williams's father dealing with dialysis treatments, influenced the lyrics of "The Birds Don't Sing". Pusha T revealed that Malice came up with the title, inspired by writer and activist Maya Angelou's 1969 autobiography I Know Why the Caged Bird Sings. Other topics included the brothers' father giving Malice his blessing to return to Clipse, the "coke rap" label often assigned to them, and Pusha T being referenced by Kendrick Lamar in his 2024 rap battle with Drake. Additionally, a comeback album was officially announced for the first time, although no title or release date was given. Pusha T stated: "The next year is going to be filled with appearances, touring, and a rap album of the year." Clipse spoke to Njera Perkins of People in an interview published on August 15, 2024. They talked about their then-upcoming performance at the Pepsi Dig In Day Block Party charity event, they joys of performing live in general, and how Williams had been pushing for a reunion.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.
NMN is the immediate precursor to NAD+ in the salvage pathway. The enzyme NMN adenylyltransferase adds an adenylate group to NMN to form NAD+. Because NAD+ levels decline with age in some tissues, researchers study whether raising NMN availability can influence NAD+ metabolism.
No. Human evidence is limited, and no regulatory agency has approved NMN for treating or preventing aging. Some trials measure NAD+ metabolites or metabolic markers, but their results do not establish a clinical benefit. Larger, longer studies with standardized endpoints are needed.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.